The progress of CAR-T cell therapy in hematologic malignancies has spurred the development of CAR-T cell therapy for solid tumors, comprising more than 90% of all malignancies and posing a significant threat to global health. Currently, there are approximately 200 ongoing clinical trials investigatin...
Clinical Trials Day One Monday 9:00 Enroll a new participant The CRO enrols Beverley, a new patient into a clinical trial for a new oncology drug. Clinical Trials Day One Monday 10:00am They are sent a Current Health kit configured to their clinical condition, including the continuous...
clinical trials of CAR-T cells in MM with the most advanced autologous BCMA-directed ide-cel and cilta-cel, the human CARs orva-cel and CT053, the alternative manufacturing process with P-BCMA-101 and bb21217, the dual CAR GC012F and the allogenic BCMA-directed CAR-T cells ALLO-715...
Decentralized clinical trials Commercial deployment Platform Platform overview Technology Remote patient monitoring Telehealth and patient engagement Clinical dashboard Integrations Services Logistics management Clinical Command Center Clinical research Professional services About Why partner with us Customers Company ...
T Luebke,J Brunkwall 摘要: In the most recent and most comprehensive meta-analyses comparing carotid endarterectomy (CEA) with carotid angioplasty and stenting (CAS), the results of 15 randomized controlled studies (RCT) are summarized. Concerning the short-term outcomes CAS was associated with a...
Oncolytic virus therapy and genetically engineered T-cell therapy for cancer are being actively developed and examined in investigator-initiated trials.This review analyzes the domestic and international clinical trial registries to comprehensively collect information on clinical trials of gene and cellular ...
we explore the challenges of applying CAR-T cell therapy to solid tumors by analyzing relevant preclinical studies and clinical trials. This review aims to propose potential strategies to overcome challenges and enhance the efficacy and applicability of CAR-T cell therapies in treating solid malignancie...
As one of the four major pharmacometric research methods257, the strategy of waiving clinical trials through PBPK study has been extensively accepted in western society and is gradually being accepted in China. 5.1.1. Basic concepts of PBPK PBPK can be utilized to mechanistically understand and ...
clinical trials25. Excitingly, preliminary results from clinical trials using dual-targeted CAR-T cells (CD19/CD22 or CD19/BCMA) have demonstrated promising results48,49,50,51. More specifically, preliminary clinical trial results of CD19/CD22 CAR-T cell therapy have demonstrated promising ...
where CAR-T cells have faced challenges [25]. By searching “CAR-NK cells” in “ClinicalTrials.gov”, we can hit 50 results in last 5 years and these ongoing trials have fueled optimism for CAR-NK therapy’s applicability across a spectrum of cancers, including solid tumors (Table1). ...